AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Siglinu M 50/1000 Tablet SR

Prescription Icon
Prescription Required

Marketer

Inuen Healthcare Pvt Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (1000mg)

Overview Siglinu M 50/1000 Tablet SR

Duo-Med 50/1000 Extended-Release tablets combine two medications to manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps mitigate serious diabetic complications, such as renal impairment and vision loss, and may lessen the risk of cardiovascular events. Duo-Med 50/1000 ER may be used independently or in conjunction with other antidiabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is personalized based on your health status, blood glucose readings, and other medications. Consuming the tablets with food minimizes gastrointestinal discomfort. Consistent daily dosing at the same time maximizes therapeutic benefits; discontinuation should only occur under your physician's guidance. Adherence to your prescribed diet and exercise plan is crucial for effective diabetes management. Common side effects include nausea, diarrhea, vomiting, stomach upset, headache, and pharyngitis. Hypoglycemia is a potential side effect, particularly when used with insulin or sulfonylureas; learn to identify and manage this complication. This medication isn't suitable for everyone. Inform your doctor of any pre-existing kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption before starting treatment. Pregnant or lactating individuals should seek medical advice. Interactions with other medications are possible; disclose all medications to your physician. Alcohol consumption should be minimized due to its hypoglycemic effect. Your doctor will monitor kidney function and blood glucose levels throughout treatment.

Primary Ingredients of Siglinu M 50/1000 Tablet SR

No information provided. Please provide the text you wish me to rephrase.

Uses of Siglinu M 50/1000 Tablet SR

Managing type 2 diabetes

Major Benefits of Siglinu M 50/1000 Tablet SR:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the Siglinu M 50/1000 Tablet SR whole; avoid chewing, crushing, or fracturing it. Administer this medication with a meal.

Common Side effects of Siglinu M 50/1000 Tablet SR:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Siglinu M 50/1000 Tablet SR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Siglinu M 50/1000 Tablet SR whole; do not damage the tablet by chewing, crushing, or breaking it. Administer this medication with food.

How Siglinu M 50/1000 Tablet SR works:

Siglinu M 50/1000 SR tablets combine sitagliptin and metformin to manage blood sugar. Sitagliptin boosts insulin production, improves insulin utilization, and lessens hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and enhances insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent alcohol use with Siglinu M 50/1000 Tablet SR is contraindicated.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Siglinu M 50/1000 SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible dangers prior to prescribing. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Siglinu M 50/1000 tablets are likely not safe for use while breastfeeding. Available human data indicate potential transfer of the medication into breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.

KidneyKidneyCAUTION

Patients with kidney impairment should use Siglinu M 50/1000 SR tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates the use of Siglinu M 50/1000 SR tablets. Physician consultation is recommended. Regular kidney function monitoring is advised during treatment.

LiverLiverUNSAFE

Patients with liver impairment should likely abstain from Siglinu M 50/1000 SR tablets; this medication may pose unacceptable risks. Medical advice is recommended.

What if you forget to take Siglinu M 50/1000 Tablet SR :

Should you forget a Siglinu M 50/1000 Tablet SR dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Siglinu M 50/1000 Tablet SR

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Siglinu M 50/1000 Tablet SR

Siglinu M 50/1000 SR tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged use of Siglinu M 50/1000 Tablet SR can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left untreated, may result in anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and urinary issues), cognitive changes, and balance problems (ataxia). To mitigate this risk, supplemental vitamin B12 intake, at least annually, is recommended by some researchers.
Siglinu M 50/1000 Tablet SR may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Patients allergic to Siglinu M 50/1000 Tablet SR components or excipients should not use it. Similarly, its use is contraindicated in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Siglinu M 50/1000 Tablet SR with alcohol is unsafe and may raise the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitagliptin/Metformin (like Siglinu M 50/1000 Tablet SR) can cause lactic acidosis, a serious medical emergency involving high blood lactic acid levels (also known as MALA, Metformin-associated lactic acidosis). This rare side effect necessitates avoiding this medication in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If these symptoms occur, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Siglinu M 50/1000 SR tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Siglinu M 50/1000 Tablet SR may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Siglinu M 50/1000 Tablet SR is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Siglinu M 50/1000 Tablet SR with alcohol is unsafe and may raise your risk of lactic acidosis.
Sitagliptin/Metformin (like Siglinu M 50/1000 Tablet SR) can cause lactic acidosis, a serious, potentially fatal buildup of lactic acid in the blood (also known as MALA). This rare side effect is more likely in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If you experience these, discontinue Sitagliptin/Metformin immediately and seek urgent medical attention.
Prolonged use of Siglinu M 50/1000 Tablet SR can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and balance problems), if left unaddressed. Therefore, annual supplemental vitamin B12 intake is recommended by some researchers to mitigate these risks.
Store this medication in its original, tightly closed container as directed on the label. Dispose of any unused medication properly and keep it out of reach of children, pets, and others.
Siglinu M 50/1000 SR tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18 years old.
Siglinu M 50/1000 Tablet SR may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Siglinu M 50/1000 Tablet SR components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Siglinu M 50/1000 Tablet SR with alcohol is unsafe and may raise your risk of lactic acidosis.
Sitagliptin/Metformin (like Siglinu M 50/1000 Tablet SR) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA, or Metformin-associated lactic acidosis). This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume large quantities of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin immediately and seek medical attention.
Prolonged use of Siglinu M 50/1000 Tablet SR can lead to vitamin B12 deficiency by impairing its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, supplemental vitamin B12 is recommended at least annually, according to some research.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Siglinu M 50/1000 Tablet ...
173